Employers’ most commonly offered digital health benefits address health issues that employees rarely report as top health goals, according to a new report.
In late 2017, Castlight partnered with Employee Benefit News to poll employers and employees for trends in the digital health ecosystem. The study, “State of the Digital Health: 2018 Annual Report,” surveyed more than 300 benefits leaders and 1,000 employees, both from large companies (defined as more than 1,000 employees).
The study was conducted to discover how employers and employees perceive digital health and benefits, how their perspectives align or differ, and the key opportunities for employers implementing digital health. For this study, employers and employees were surveyed on 23 discrete categories of digital health, which collectively addressed the full spectrum of care. The categories are grouped into three areas: staying healthy, managing conditions and accessing care.
“Healthcare is too complex and too expensive, and, as a result, too few people are getting the right care at the right time,” says Derek Newell, president of Castlight. “Most Americans get their health coverage from their employer, and so employers have a big opportunity to help people navigate the complicated healthcare landscape. Our report shows that there is a big missed opportunity in that regard. The benefits employers are most likely to offer are rarely the ones that meet employee health needs.”
None of the top goals employees named-weight loss, save for retirement/reduce debt, reduce stress, sleep better, improve nutrition, walk more, etc.-were among the top priorities identified by benefit leaders. The study also reveals that employees are accessing those tools, just doing so directly rather than with their employer.
Other unique findings from the report include:
Based on the report, Newell offers these three takeaways for healthcare executives:
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More